The S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. In afternoon trade, the benchmark index is down 0.6% to 8,821 points.
Four ASX shares that have not let that hold them back today are listed below. Here's why they are rising:
Image source: Getty Images
Bellevue Gold Ltd (ASX: BGL)
The Bellevue Gold share price is up 3% to $1.75. Investors have been buying this gold miner's shares following the release of its quarterly update. The company reported a 10% increase in quarterly gold production to 32,031 ounces with gold poured of 31,656 ounces. Bellevue Gold also revealed that its gold sold totalled 31,905 ounces at an average realised price of A$4,292 per ounce. This was achieved with a project all-in sustaining cost (AISC) reducing to A$2,989/oz. Management expects its AISC to reduce further through the second half in line with its FY 2026 guidance.
DroneShield Ltd (ASX: DRO)
The DroneShield share price is up 5% to $4.79. This is despite there being no news out of the counter-drone technology company. However, with tensions rising in Europe in relation to the Donald Trump's bid to take over Greenland, investors may believe that demand for counter-drone technology could increase. In other news, last week, DroneShield was selected as a supplier for the Australian Department of Defence's Project LAND 156's Line of Effort 3. This will support the Defence's strategy to address evolving threats posed by small drones in domestic security.
Hub24 Ltd (ASX: HUB)
The Hub24 share price is up 4% to $102.49. This follows the release of its second quarter update this morning. The investment platform provider revealed record net inflows of $5.6 billion. This helped lift total funds under administration (FUA) to a new high of $152.3 billion at the end of December. The company stated: "Strong momentum in 1HFY26 reflects continued opportunities for growth driven by ongoing demand for professional advice in addition to industry transformation. HUB24 remains committed to investing to deliver our strategy to capitalise on these opportunities and further enhance our market leading proposition."
Telix Pharmaceuticals Ltd (ASX: TLX)
The Telix Pharmaceuticals share price is up 3% to $11.64. This has been driven by positive news out of China. The radiopharmaceuticals company revealed that Chinese regulators have accepted the New Drug Application for its lead imaging agent for prostate cancer, Illuccix. It advised that the pivotal phase 3 study in China reported a positive predictive value of 94.8%. It also showed a change in treatment for over two-thirds of patients. Telix's CEO of Precision Medicine, Kevin Richardson, said: "Geographic expansion is core to the growth strategy for our precision medicine business, and China represents a strategically important market for Telix."
